| Drug Name |
Ipilimumab |
| Drug ID |
BADD_D01190 |
| Description |
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).[L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126]
Ipilimumab was granted FDA approval on 25 March 2011.[L12126] |
| Indications and Usage |
Ipilimumab is indicated to treat unresectable or metastatic melanoma, as an adjuvant in the treatment of cutaneous melanoma, to treat microsatellite-high or mismatch repair deficient metastatic colorectal cancer, or to treat hepatocellular carcinoma.[L12126] Ipilimumab with [nivolumab] is indicated to treat advanced renal cell carcinoma.[L12126] |
| Marketing Status |
approved |
| ATC Code |
L01FX04 |
| DrugBank ID |
DB06186
|
| KEGG ID |
D04603
|
| MeSH ID |
D000074324
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D07BVI
|
| NDC Product Code |
0952-2327; 71124-0001; 0003-2328; 71124-0020; 71124-0021; 0003-2327; 71124-0022; 83157-2327 |
| UNII |
6T8C155666
|
| Synonyms |
Ipilimumab | Anti-CTLA-4 MAb Ipilimumab | Anti CTLA 4 MAb Ipilimumab | Ipilimumab, Anti-CTLA-4 MAb | Yervoy | MDX 010 | MDX010 | MDX-010 | MDX-CTLA-4 | MDX CTLA 4 |
